Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).
Condition | Intervention | Phase |
---|---|---|
Myelodysplastic Syndrome (MDS) |
Drug: Azacitidine |
Phase 2 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Chinese Subjects With Higher-Risk Myelodysplastic Syndromes |
- Proportion of participants achieving a hematologic response defined as Complete Response (CR), Partial Remission(PR), Stable Disease(SD) and Hematologic Improvement based on International Working Group 2000 response criteria for Myelodysplastic Syndromes [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]Proportion of participants achieving a hematologic response defined as Complete Response (CR), Partial Remission(PR), Stable Disease(SD) and Hematologic Improvement based on International Working Group 2000 response criteria for Myelodysplastic Syndromes
- Number of platelet transfusions [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]Number of platelet transfusions
- Number of red blood cell transfusions [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]Number of red blood cell transfusions
- Number of infections requiring intravenous antibiotics [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]Number of infections requiring intravenous antibiotics
- Adverse Events [ Time Frame: Up to 12 months ] [ Designated as safety issue: Yes ]Number of participants with adverse events (type, frequency, severity, and relationship of adverse events to study treatment; physical examinations, vital signs; clinical laboratory evaluations, and concomitant medication/therapy)
- Steady-state plasma azacitidine concentrations [ Time Frame: 3 days ] [ Designated as safety issue: No ]Steady-state plasma azacitidine concentrations
- Number of participants who survive [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]Number of participants who survive
Estimated Enrollment: | 70 |
Study Start Date: | May 2012 |
Estimated Study Completion Date: | November 2014 |
Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Azacitidine
As indicated in Intervention description
|
Drug: Azacitidine
Subcutaneous administration of azacitidine 75 mg/m2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
Other Name: Vidaza
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
- Chinese males and females of Asian descent ≥ 18 years of age at the time of signing the informed consent document;
Must have a documented diagnosis of refractory anemia with excess blasts (RAEB) or refractory anemia with excess blasts in transformation (RAEB-T) according to French-American-British (FAB) classification for MDS (Appendix A) and with an International Prognostic Scoring System (IPSS) score of intermediate-2 or high risk (Appendix D) or a diagnosis of myelodysplastic chronic myelomonocytic leukemia (CMML) per modified FAB criteria meeting the following:
- Monocytosis in peripheral blood > 1 x 109/L;
- Dysplasia in one or more myeloid cell lines;
- 10% to 29% blasts in the bone marrow; and White blood cell (WBC) count < 13 x 109/L
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (see Appendix C);
- Adequate organ function, defined as:
- Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN);
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.0 times the ULN;
- Serum creatinine ≤ 1.5 times the ULN;
- Females of childbearing potential (FCBP) must:
- Agree to the use of a physician-approved contraceptive method (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on azacitidine; and
- for 3 months following the last dose of azacitidine; and have a negative serum pregnancy test within 72 hours prior to starting IP.
- Male subjects with a female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of azacitidine;
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted;
- Able to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
- Previous treatment with azacitidine or decitabine;
- Diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma of the skin without complications, "in-situ" carcinoma of the cervix or breast,or other local malignancy excised or irradiated with a high probability of cure);
- Uncorrected red cell folate deficiency or vitamin B12 deficiency;
- Diagnosis of metastatic disease;
- Malignant hepatic tumors;
- Known or suspected hypersensitivity to azacitidine or mannitol;
- Candidate to proceed to bone marrow or stem cell transplant during the study;
- Prior transplantation or cytotoxic therapy, including azacitidine and chemotherapy,administered to treat MDS;
- Treatment with erythropoietin or myeloid growth factors (granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF]) during the 21 days prior to Day 1 of Cycle 1;
- Treatment with androgenic hormones during the 14 days prior to Day 1 of Cycle 1;
- Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C;
- Treatment with other investigational drugs, including thalidomide and arsenic trioxide,within the previous 30 days prior to Day 1 of Cycle 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period; and
- Pregnant or lactating females;
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study;
- Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study;
- Any condition that confounds the ability to interpret data from the study.
Contact: Anoula Galettis, APAC | +61 408 674 720 | agalettis@celgene.com |
Contact: Lili Meng | +86 20 3766 7400 | lili.meng@tigermed.net |
China | |
Peking University People's Hospital | Not yet recruiting |
Beijing, China, 100044 | |
Peking University Third Hospital | Not yet recruiting |
Beijing, China, 100191 | |
West China Hospital, Sichuan University | Recruiting |
Chengdu, China, 610041 | |
Guangdong General Hospital | Recruiting |
Guangzhou, China, 510080 | |
Chinese PLA General Hospital | Not yet recruiting |
Haidian district, China, 100853 | |
The First Hospital Affiliated of College Medicine, Zhejiang University | Recruiting |
Hangzhou, China, 310003 | |
Shanghai 6th People's Hospital | Not yet recruiting |
Shanghai, China, 200233 | |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting |
Shanghai, China, 200025 | |
The First Affiliated Hospital of Soochow University | Not yet recruiting |
Suzhou, China, 215006 | |
Institute of Haematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College | Not yet recruiting |
Tianjin, China, 300020 | |
Wuhan Union Hospital Tonji Medical College Huazhong University of Science and Technology | Recruiting |
Wuhan,, China, 430000 |
Study Director: | C L Beach | Celgene Corporation |
No publications provided
Responsible Party: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT01599325 History of Changes |
Other Study ID Numbers: | AZA-MDS-002 |
Study First Received: | May 14, 2012 |
Last Updated: | September 28, 2012 |
Health Authority: | China: State Food and Drug Administration |
Additional relevant MeSH terms:
Myelodysplastic Syndromes Preleukemia Bone Marrow Diseases Hematologic Diseases Precancerous Conditions Neoplasms Azacitidine |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors |
ClinicalTrials.gov processed this record on October 17, 2012